{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rajasekhar M"],"funding":["Wellcome Trust","Intramural CDC HHS"],"pagination":["184-195"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7615565"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(2)"],"pubmed_abstract":["<h4>Background</h4>Primaquine radical cure is used to treat dormant liver-stage parasites and prevent relapsing Plasmodium vivax malaria but is limited by concerns of haemolysis. We undertook a systematic review and individual patient data meta-analysis to investigate the haematological safety of different primaquine regimens for P vivax radical cure.<h4>Methods</h4>For this systematic review and individual patient data meta-analysis, we searched MEDLINE, Web of Science, Embase, and Cochrane Central for prospective clinical studies of uncomplicated P vivax from endemic countries published between Jan 1, 2000, and June 8, 2023. We included studies if they had active follow-up of at least 28 days, if they included a treatment group with daily primaquine given over multiple days where primaqu"],"journal":["The Lancet. Infectious diseases"],"pubmed_title":["Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis."],"pmcid":["PMC7615565"],"funding_grant_id":["CC999999","093956/Z/10/Z","200909","093956/Z/10/C","223253/Z/21/Z"],"pubmed_authors":["Green JA","Chau NH","Rijal KR","Saravu K","Karunajeewa H","Bancone G","von Seidlein L","Adhikari B","Price RN","Naadim MN","Taylor WRJ","Boyd SC","Ghimire P","Ladeia-Andrade S","Baird JK","Degaga TS","Nosten F","Khan WA","Abreha T","Anstey NM","Awab GR","Watson JA","Chu CS","Guerin PJ","Woyessa A","Assefa A","WorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study Group","Simpson JA","Barber BE","Grigg MJ","Llanos-Cuentas A","Koh GC","Ferreira MU","Dondorp AM","Alam MS","Thriemer K","Commons RJ","William T","Hwang J","Lacerda MVG","Pasaribu AP","Price DJ","Day NP","Rajasekhar M","Woodrow CJ","Sutanto I","Mekuria AH","Pukrittayakamee S","Ley B","Nelwan EJ","Edler P","Stepniewska K","White NJ"],"additional_accession":[]},"is_claimable":false,"name":"Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.","description":"<h4>Background</h4>Primaquine radical cure is used to treat dormant liver-stage parasites and prevent relapsing Plasmodium vivax malaria but is limited by concerns of haemolysis. We undertook a systematic review and individual patient data meta-analysis to investigate the haematological safety of different primaquine regimens for P vivax radical cure.<h4>Methods</h4>For this systematic review and individual patient data meta-analysis, we searched MEDLINE, Web of Science, Embase, and Cochrane Central for prospective clinical studies of uncomplicated P vivax from endemic countries published between Jan 1, 2000, and June 8, 2023. We included studies if they had active follow-up of at least 28 days, if they included a treatment group with daily primaquine given over multiple days where primaqu","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2026-07-15T02:35:58.694Z","creation":"2026-06-28T03:07:36.6Z"},"accession":"S-EPMC7615565","cross_references":{"pubmed":["37748497"],"doi":["10.1016/S1473-3099(23)00431-0"]}}